National Institutes of Health has awarded AttoDx $220,230, one-year, Phase 1 Small Business Technology Transfer grant from the National Institute of Allergy and Infectious Disease. AttoDx wil develop an assay in collaboration with Claremont BioSolutions and researchers at the University of Washington, initially for same-day smear-negative and extrapulmonary Mycobacterium tuberculosis from sputum and cerebrospinal fluid of HIV-co-infected patients.
Dead or Alive: Molecular Assessment of Microbial Viability. Cangelosi GA1, Meschke JS2.
AttoDx, Inc. has relocated its laboratories and administrative offices to the Center for Infectious Disease Research building, located in the South Lake Union area of downtown Seattle. The new address is 307 Westlake Ave. N, Seattle, WA 98109-5219. Phone (206) 200-8541, Fax (206) 337-8527.
Washington State's Life Sciences Discovery Fund has awarded a grant for Improved diagnosis of healthcare-associated infections to Dr. Jerry Cangelosi at the University of Washington's public school of health and AttoDx, Inc.
AttoDX Vice President of Product Development, Paul Harris has built and tested economical, efficient compact prototypes of a 12-channel nucleic acid extraction system. This system is being designed to work with various nucleic acid extraction devices optimized for molecular viability testing that will have a wide variety of applications. In addition, Dr. Harris has designed and built a prototype concentration instrument that is currently being assessed for concentrating MS2 viruses in water samples.
AttoDx has achieved a major milestone in the development of the most sensitive molecular diagnostic tests for bacterial pathogens.Targeting diverse bacterial species in human serum and other samples, the company demonstrated a level of sensitivity that is approximately 100-fold better than the industry standard real-time PCR method. AttoDx’s Molecular Viability Testing (MVT) technology induces bacteria in clinical samples to rapidly produce large quantities of an RNA biomarker. This activity increases the visibility of living bacteria while eliminating the erroneous detection of dead bacteria. The enhanced sensitivity and specificity of MVT reduces the window of uncertainty that limits the performance of current molecular diagnostic tests.
AttoDX added two individuals, Chuck Grindstaff and Mark Legaz, to the BusinessAdvisory Board to help formulate AttoDx’s business strategy. Chuck Grindstaff is Chief Executive Officer for Siemens PLM Software, a business unit of the Siemens Industry Automation Division. In October 2010, Mr.Grindstaff was appointed president, while also retaining his position as Chief Technology Officer. In October 2011, he assumed the role of CEO. He has a B. A.in biochemistry. Dr. Mark Legaz is the President and CEO of Intersect Systems, Inc., a medical diagnostic products company, and is the Founder and Consultant to Catch, Inc, of Seattle,Washington, whose diagnostic technologies were acquired by Axis-Shield of Scotland. Dr. Legaz is a research biochemist with over 40 years of academic and corporate experience. He has developed and obtained FDA clearance for over 20 reagent formulations utilizing a combination of mammalian and microbial enzymes. Products developed by Dr. Legaz’s ventures, are sold by Bayer, Olympus, Beckman, Roche, Genzyme, Medical Analysis Systems, Johnson and Johnson, Technicon and Carolina Liquid Chemistries. He received a B.A. in chemistry from the University of San Diego, California; a Ph.D. in biochemistry from the University of Washington in Seattle; and did his postdoctoral research in clinical chemistry at the University of Washington.
AttoDx has agreed to cross license technologies with Blood Cell Storage, Inc of Seattle, Washington. Read More.
AttoDx has signed an agreement with the University of Washington and Seattle Biomedical Research Institute (now Center for Infection Disease Research) for an exclusive license to molecular viability testing that will be used in the development of pathogen-detection products for food, water and the environment. Read More.